Literature DB >> 15827969

Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry.

Vilma Habrdova1, Frank T Peters, Denis S Theobald, Hans H Maurer.   

Abstract

In recent years, several newer designer drugs of the so-called 2C series such as 2C-D, 2C-E, 2C-P, 2C-B, 2C-I, 2C-T-2, and 2C-T-7 have entered the illicit drug market as recreational drugs. Some fatal intoxications involving 2C-T-7 have been reported. Only scarce data have been published about analyses of these substances in human blood and/or plasma. This paper describes a method for screening and simultaneous quantification of the above-mentioned compounds and their analog mescaline in human blood plasma. The analytes were analyzed by gas chromatography/mass spectrometry in the selected-ion monitoring mode, after mixed-mode solid-phase extraction (HCX) and derivatization with heptafluorobutyric anhydride. The method was fully validated according to international guidelines. Validation data for 2C-T-2 and 2C-T-7 were unacceptable. For all other analytes, the method was linear from 5 to 500 microg/L and the data for accuracy (bias) and precision (coefficient of variation) were within the acceptance limits of +/-15% and <15%, respectively (within +/-20% and <20% near the limit of quantification of 5 microg/L).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827969     DOI: 10.1002/jms.853

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  2 in total

Review 1.  Microwave-assisted derivatization procedures for gas chromatography/mass spectrometry analysis.

Authors:  Sandra L Söderholm; Markus Damm; C Oliver Kappe
Journal:  Mol Divers       Date:  2010-03-12       Impact factor: 2.943

2.  Identification of designer drug 2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose.

Authors:  Michael J Van Vrancken; Raul Benavides; Frank H Wians
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.